马来酸曲美布汀联合抗抑郁焦虑药物治疗肠易激综合征的的疗效观察.docVIP

马来酸曲美布汀联合抗抑郁焦虑药物治疗肠易激综合征的的疗效观察 　　[摘要] 目的:评价马来酸曲美布汀联合抗抑郁焦虑药物(黛力新、艾司唑仑)治疗肠易激综合征(IBS)的疗效。方法:将75例肠易激综合征患者随机分为两组,治疗组采用马来酸曲美布汀联合黛力新、艾司唑仑治疗,对照组单用马来酸曲美布汀治疗,疗程均为4周。治疗前后进行消化道症状、SDS和HAMA量表评分。结果:治疗组消化道症状积分、SDS和HAMA量表评分下降显著高于对照组。治疗组总有效率为86.8%,对照组为54.1%,两组比较,差异有统计学意义(P0.05)。结论:使用马来酸曲美布汀、黛力新、艾司唑仑联合治疗能有效缓解肠易激综合征(IBS)的症状。 　　[关键词] 肠易激综合征;马来酸曲美布汀;黛力新;艾司唑仑 　　[中图分类号]R574.4 [文献标识码]B[文章编号]1673-7210(2010)04(c)-096-03 　　 　　Clinical observation on Trimebutine maleate combined Deanxit treated patients with irritable bowel syndrome 　　SUN Chenming, WANG Ping, WU Jie, ZHANG Heng 　　(Department of Digestive System, the Central Hospital of Wuhan, Wuhan 430014, China) 　　[Abstract] Objective: To evaluate the effect of trimebutine maleate combined with deanxit and estazolam in the treatment of patients with irritable bowel syndrome. Methods: 75 cases of IBS were randomly divided into 2 groups, the treatment group took trimebutine maleate combined with deanxit and estazolam, and the control group only took trimebutine maleate. The time of the treatment was 4 weeks. The gastrointestinal symptoms scores, SDS and HAMA were used for evaluation before and after treatment. Results: The gastrointestinal symptoms scores, SDS and HAMA declined evidently in the treament group compared with the control group. The total efficacy rate was 86.8% in the treament group and 54.1% in the control group. The diffirence of the two groups had statistical significance (P0.05). Conclusion: It is assumed that the treatment with trimebutine maleate combined with deanxit and estazolam could ameliorate the symptom of IBS efficiently. 　　[Key words] Irritable bowel syndrome; Trimebutine maleate; Deanxit; Estazolam 　　 　　肠易激综合征(irritable bowel syndrome, IBS)是一种常见的消化系统症候群,发病率高,其人群总体发生率为10%～15%,年发病率为1%～2%[1]。患者常表现为腹痛、腹部不适以及排便习惯改变等症状,也常伴有失眠、焦虑、恐慌等临床表现。症状持续或间歇发作,治疗困难。目前用于治疗IBS的药物虽然较多,但尚无一种药物对所有的IBS患者有确切的疗效[2]。2007年12月～2009年1月笔者采用马来酸曲美布汀联合氟哌噻吨美利曲辛(商品名:黛力新)、艾司唑仑治疗IBS,疗效观察如下: 　　1 资料与方法 　　1.1 一般资料 　　我科2007年12月～2009年1月门诊收治住院患者7